Pr MD - Minerva Neurosciences Chief Officer

Minerva Neurosciences Management Efficiency

The company has return on total asset (ROA) of (0.2891) % which means that it has lost $0.2891 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (6.7509) %, meaning that it created substantial loss on money invested by shareholders. Minerva Neurosciences' management efficiency ratios could be used to measure how well Minerva Neurosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to climb to 1.11 in 2024, whereas Return On Tangible Assets are likely to drop (0.75) in 2024. At this time, Minerva Neurosciences' Total Assets are fairly stable compared to the past year. Total Current Assets is likely to climb to about 52.9 M in 2024, whereas Other Assets are likely to drop slightly above 1.3 M in 2024.

Similar Executives

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts. Minerva Neuroscie operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 9 people. Minerva Neurosciences (NERV) is traded on NASDAQ Exchange in USA. It is located in 1500 District Avenue, Burlington, MA, United States, 01803 and employs 9 people. Minerva Neurosciences is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Minerva Neurosciences Leadership Team

Minerva Stock Performance Indicators

Additional Tools for Minerva Stock Analysis